Research abuses against people of colour and other vulnerable groups in early psychedelic research
Dana Strauss, Sara de la Salle, Jordan Sloshower, Monnica T. Williams
Journal of Medical Ethics July 12, 2021 DOI: 10.1136/medethics-2021-107262 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | People of colour, incarcerated individuals, and inpatients with psychotic disorders in the USA (1950-1980) |
| Citations | 70 |
| Key findings | Historical US psychedelic research exploited people of colour and other vulnerable populations through questionable methods, lack of informed consent, and covert CIA funding. |
Abstract
There is a growing resurgence in the study of psychedelic medicines for the treatment of mental health and substance use disorders. However, certain early investigations are marred by questionable research methods, abuses against research participants, and covert Central Intelligence Agency financial involvement. The purpose of this study was to understand how and to what extent people of colour and other vulnerable populations, specifically, individuals who were incarcerated or incapacitated due to mental health issues (inpatients with psychotic disorders), were exploited during the first wave of psychedelic research in the USA (1950-1980). To do so, we reviewed available empirical publications according to current ethical standards. Variables of interest included race and ethnicity of participants, population vulnerability, drug administration conditions, informed consent and undue influence. Our findings draw attention to the history of research abuses against people of colour in Western psychedelic research. In light of these findings, we urge a call-to-action to current psychedelic researchers to prioritise culturally inclusive and socially responsible research methods in current and future studies.
Citations in the library
Cited by 54
- The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision Frontiers in Psychiatry January 20, 2022
- Ethnoracial inclusion in clinical trials of psychedelics: a systematic review. EClinicalMedicine August 1, 2024
- Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychopathological Psychotic Experiences and Psychotic Disorders International Journal of Mental Health and Addiction April 1, 2024
- MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial Journal of Psychopharmacology June 21, 2022
- Giving consent to the ineffable Neuroethics February 15, 2024
and 49 more in the library
Cites 22
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology April 26, 2017
- Global Street Food: la cocina de la calle Diseño interior 2009
- Better Biomarkers, Faster Drugs, Stronger Models: Progress Towards Precision Psychiatry. Missouri medicine 2023
- Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials Journal of Psychopharmacology March 8, 2012
and 17 more in the library